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Purpose
Pancreatic cancer (PC) is one of the most lethal cancers worldwide, but there are currently
no effective treatments. The DNA damage response (DDR) is under investigation for the 
development of novel anti-cancer drugs. Since DNA repair pathway alterations have been
found frequently in PC, the purpose of this study was to test the DDR-targeting strategy in
PC using WEE1 and ATM inhibitors.
Materials and Methods
We performed in vitro experiments using a total of ten human PC cell lines to evaluate anti-
tumor effect of AZD1775 (WEE1 inhibitor) alone or combination with AZD0156 (ATM inhi-
bitor). We established Capan-1–mouse model for in vivo experiments to confirm our findings.
Results
In our research, we found that WEE1 inhibitor (AZD1775) as single agent showed anti-tumor
effects in PC cells, however, targeting WEE1 upregulated p-ATM level. Here, we observed
that co-targeting of WEE1 and ATM acted synergistically to reduce cell proliferation and 
migration, and to induce DNA damage in vitro. Notably, inhibition of WEE1 or WEE1/ATM
downregulated programmed cell death ligand 1 expression by blocking glycogen synthase
kinase-3! serine 9 phosphorylation and decrease of CMTM6 expression. In Capan-1 mouse
xenograft model, AZD1775 plus AZD0156 (ATM inhibitor) treatment reduced tumor growth
and downregulated tumor expression of programmed cell death ligand 1, CMTM6, CD163,
and CXCR2, all of which contribute to tumor immune evasion.
Conclusion
Dual blockade of WEE1 and ATM might be a potential therapeutic strategy for PC. Taken
together, our results support further clinical development of DDR-targeting strategies for
PC.
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Introduction
Pancreatic cancer (PC) is one of the most lethal diseases
worldwide, and there is an urgent need to develop effective
therapies for this disease [1,2]. Recently, genomic analyses
have revealed that many cancer susceptibility genes are fre-
quently mutated in PC, including KRAS (92% of cases) and
TP53 (78%). In addition, germline and somatic mutations in
genes encoding breast cancer 1 and 2 (BRCA1, BRCA2), ataxia
telangiectasia mutated (ATM) and partner and localizer of
BRCA2 (PALB2) are present in PC patients with frequencies
of 5% (germline mutations) and 12% (somatic mutations) [1].
These genes play critical roles in the DNA damage response
(DDR), which signals the presence of strand breaks and other
forms of DNA damage and coordinates their repair. Para-
doxically, mutations in genes that compromise the DDR can
both cause and protect against cancer. On the one hand, 
defects in the DDR can lead to genomic instability and the
accumulation of mutations that increase the probability of
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cancer. On the other hand, DDR pathway dysfunction can
render tumor cells susceptible to chemotherapeutic agents
that damage DNA and/or impair alternative DDR pathways
[3]. Thus, targeting of specific molecules in the DDR is a 
potential strategy for the development of new drugs for can-
cers with urgent unmet needs, including PC. 
The cellular response to DNA damage, including single-
stranded or double-stranded DNA breaks, is controlled by a
network of proteins that include damage-sensing proteins
such as poly(ADP-ribose) polymerase (PARP); transducers
such as the kinases ATM and ataxia telangiectasia and Rad3
related (ATR); and effectors such as the nuclear kinase WEE1,
which is a key protein in cell cycle checkpoint control and 
inhibits entry into mitosis [3]. Ultimately, the DDR results in
one of three outcomes for the cell: successful DNA repair, cell
cycle arrest, or apoptosis. 
Therapeutic targeting of the DDR pathway has been exam-
ined in diverse tumor types [3]. Notably, inhibition of PARP,
ATM, ATR, or WEE1 has been shown to abrogate DNA 
repair via homologous recombination (HR) in many cancers
with a genetically defective DDR, thus leading to synthetic
lethality [4-7]. WEE1 acts as a gatekeeper of the G2/M cell
cycle checkpoint, and its activity increases during the S and
G2 phases; thus, WEE1 inhibition can induce growth arrest
in S phase [8]. In contrast, cancer cells expressing mutant
TP53 lack a functional G1 checkpoint, and DNA damage
must be repaired during the G2/M transition. Given that
TP53 is often mutated in PC [8], PC is the good candidate for
the development of the DDR-acting agents.
The tumor microenvironment plays a critical role in cancer
progression [9]. PC is unique compared with other tumor
types in being surrounded by strong stroma. Abundant 
immunosuppressive cells reside in the tumor microenviron-
ment, including regulatory T cells, myeloid-derived suppres-
sor cells (MDSCs), M2-type macrophages, and cancer-asso-
ciated fibroblasts (CAFs) [9,10]. Recruitment of these cells 
establishes a barrier to the anti-tumor immune response
[9,10]. In addition, signaling via the chemokine receptor
CXCR2 can drive PC growth by recruiting MDSCs and
tumor-associated neutrophils and by enhancing the metasta-
tic process [10]. Programmed cell death ligand 1 (PD-L1) is a
negative regulator of the immune response and acts by bind-
ing to its receptor programmed cell death 1 (PD-1) on T cells,
which inactivates the cells and thus allows the tumor to 
escape immune surveillance [11]. Data from genomic analy-
ses indicate that immunogenic subtype of PC, which exhibits
high levels of PD-L1, cytotoxic T-lymphocyte-associated pro-
tein 4 and CXCR2 among several subtypes [1]. Notably, the
chemokine-like factor-like MARVEL transmembrane domain
containing family member 6 (CMTM6) has been suggested
as one of the mechanisms of regulation of PD-L1 through
preventing PD-L1 degradation by lysosome [12]. 
Increasing evidence suggests the existence of crosstalk 
between the DDR signaling network and immune pathways
[13,14]. For example, recent studies have demonstrated that
the DDR regulates PD-L1 expression in cancer cells via a
pathway involving activation of signal transducer and acti-
vator of transcription (STAT) signaling and inactivation of
glycogen synthase kinase-3! (GSK-3!) [15,16]. However,
such interactions between the DDR and immune signaling
have not yet been studied in PC.
Here, we evaluated the anti-tumor effects of targeting the
DDR using a WEE1 kinase inhibitor (AZD1775) and an ATM
kinase inhibitor (AZD0156) in PC cells in vitro and in a mouse
xenograft model. We also examined the expression and acti-
vation of a number of DDR-related and immune signaling-
related molecules to identify potential crosstalk between the
DDR and immune system in PC. 
Materials and Methods
1. Human cell lines and reagents
Ten human PC cell lines were employed in this study:
AsPC-1, Capan-1, Capan-2, MIA PaCa-2, PANC-1, SNU213,
SNU324, and SNU410 were purchased from the Korean Cell
Line Bank (Seoul, Korea), and SNU2913 and SNU2918, pati-
ent-derived cell lines, were successfully established from 
patient. Cells were cultured in medium (MIA PaCa-2 and
PANC-1 cells in Dulbecco's modified Eagle's medium, all
other cell lines in RPMI-1640, both from Welgen Inc., Gyeong-
san, Korea) supplemented with 10% fetal bovine serum and
10 µg/mL gentamicin and were maintained at 37°C in a 5%
CO2 atmosphere. The WEE1 inhibitor AZD1775 and ATM 
inhibitor AZD0156 were kindly provided by AstraZeneca
(Macclesfield, UK). 
2. PD-L1 expression analysis by flow cytometry
Cells (2!105) were seeded in 60-mm dishes and incubated
with AZD1775 and/or AZD0156 for 72 hours. The adherent
cells were harvested, resuspended in cell staining buffer
(#420201, BioLegend, San Diego, CA), and incubated with
anti–PD-L1 antibody (#329708, BioLegend) for 30 minutes at
room temperature. Cells were then washed once with the
same buffer and analyzed on a FACSCalibur. The results are
presented as the means of three independent experiments.
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3. Human cytokine array
Cells (1!106) were seeded in 60-mm dishes and exposed to
AZD1775 and/or AZD0156 for 24 hours. The cell super-
natant was then collected and 500 µL/sample was analyzed
using the Proteome Profiler Human Cytokine Array Kit
(#ARY-005B, R&D Systems, Minneapolis, MN) according to
the manufacturer’s instructions. Spot intensities were meas-
ured using ImageJ software (National Institutes of Health,
Betheda, MD).
4. Human phospho-kinase array
Cells (1!106) were seeded in 100-mm dishes and exposed
to AZD1775 and/or AZD0156 for 72 hours. The cells were
harvested, and lysate samples containing 300 µg of proteins
were analyzed using the Proteome Profiler Human Phospho-
Kinase Array Kit (#ARY003B, R&D Systems) according to
the manufacturer’s instructions. Spot intensities measured
using ImageJ software.
5. Tumor xenograft experiments
Four-week-old female athymic nude mice were purchased
from Orient Bio Inc. (Seongnam, Korea). Capan-1 cells were
resuspended at 3!107 cells in 100 µL of phosphate-buffered
saline and injected subcutaneously. The tumor volume was
calculated using the formula: volume=[(width)2!height]/2.
When the tumor volume reached 200 mm3, the mice were
randomly assigned to four groups of five mice to receive (1)
vehicle (2-hydroxypropyl-!-cyclodextrin solution), (2) AZD-
1775 once daily at 30 mg/kg for 4 weeks (5 days on/2 days
off), (3) AZD0156, as described for (2), or (4) AZD1775 plus
AZD0156, as described for (2). All treatments were adminis-
tered by oral gavage. Body weights and tumor sizes were
measured every other day.
6. Mouse cytokine array
Immediately before sacrifice, the mice were bled and serum
samples were prepared. Aliquots of 500 µL were analyzed
using the Proteome Profiler Mouse Cytokine Array Kit, Panel
A (#ARY006, R&D Systems) according to the manufacturer’s
instructions. Spot intensities were measured using ImageJ
software.
7. Statistical analysis
Analyses were conducted using SigmaPlot version 10.0
(Systat Software Inc., San Jose, CA). Data are presented as
the mean±standard errors. All statistical tests were two-
sided. Differences were considered significant if the p-values
were < 0.05. Half-maximal inhibitory concentrations (IC50)
were calculated using SigmaPlot software. Combined drug
effects were analyzed by calculating the combination index
(CI) with CalcuSyn software (Biosoft, Cambridge, UK). CI
values of < 1, 1, and > 1 indicate synergistic, additive, and
antagonistic effects, respectively.
8. Others
Further information on cell viability assay, colony-forming
assay, western blot analysis, immunoprecipitation, cell cycle
analysis, Annexin V/propidium iodide (PI) apoptosis assay,
comet assay, transwell migration assay, and immunohisto-
chemistry can be found in supplementary methods.
9. Ethical statement
Animal experiments were performed at the Biomedical
Center for Animal Resource Development of Seoul National
University (Seoul, Korea) according to institutional guide-
lines, and prior approval of the study protocol was obtained
from the Institutional Animal Care and Use Committee.
Results
1. WEE1 inhibition inhibits the proliferation of PC cells 
To evaluate the anti-tumor effects of WEE1 inhibition in
PC, we used the MTT assay to assess the proliferation of 10
human PC cell lines in the presence of AZD1775 for 72 hours.
As shown in Fig. 1A, AZD1775 inhibited the proliferation of
all PC cell lines in a dose-dependent manner. The concentra-
tions causing 50% inhibition (IC50) ranged from 0.5 to 2.1 µM
(S1 Table). To verify these data, we examined the ability of
the PC cell lines to form colonies after 10 days of incubation
with AZD1775. This analysis also indicated a profound sup-
pression of colony formation in all PC cell lines (Fig. 1B), and
the low IC50 values for colony formation (0.03-0.36 µM) con-
firmed the sensitivity of human PC cells to WEE1 inhibition
(S1 Table). Because all 10 of the PC cell lines showed compa-
rable inhibition by AZD1775, we randomly selected four cell
lines (Capan-1, SNU213, SNU410, and SNU2913) for the fol-
lowing experiments. 
To determine whether AZD1775 blocked signaling in the
DDR pathway, we performed western blot analysis of the 
expression and activation (phosphorylation) of a number of
molecules involved in DDR signaling downstream of WEE1.
For these experiments, PC cells were incubated with or with-
out AZD1775 for 24 hours before analysis by western blot-
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ting. As shown in Fig. 1C, we confirmed that AZD1775 dose-
dependently reduced the expression of total and phospho-
rylated WEE1 (p-WEE1) in all PC cells tested. In addition,
AZD1775 also decreased the expression of phosphorylated
cell division cycle protein 2, c-Myc, and phosphorylated 
nuclear factor kappa-light-chain-enhancer of activated B cells
(p–NF-kB), and upregulated the expression of !-H2AX com-
pared with control (Fig. 1C). These results suggest that AZD-
1775 monotherapy has anti-proliferative activity in PC cells.
2. WEE1 inhibition induces S-phase arrest and apoptosis in
PC cells
Since WEE1 inhibition reduced PC cell proliferation, we
next determined whether AZD1775 induced apoptosis. For
this, the cells were incubated with or without AZD1775 for
48 hours and apoptosis was examined by flow cytometry of 
Annexin V/PI–stained cells or by western blot analysis of an
apoptosis regulator, MCL-1, and an effector, cleaved caspase
7. We found that AZD1775 treatment significantly increased
the proportion of apoptotic cells compared with control cells
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Fig. 1.  Growth inhibitory effect of AZD1775 in pancreatic cancer (PC) cell lines. (A) Ten PC cell lines were exposed to control
(0) or 0.001, 0.01, 0.1, 1, and 10 µM AZD1775 for 72 hours, and cell viability was measured using the MTT assay. (B) Cell
lines were treated as described in A and colony formation was analyzed after 10 days. (C) Western blot analysis of total or
phosphorylated signaling molecules in Capan-1, SNU213, SNU410, and SNU2913 cells treated with 0, 0.1, or 1 µM AZD1775
for 24 hours. Experiments were repeated three times. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; p–NF-kB, phos-
phorylated nuclear factor kappa-light-chain-enhancer of activated B cells. (Continued to the next page)
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Fig. 1.  (Continued from the previous page) (D) Annexin V/propidium iodide (PI) apoptosis assay of Capan-1, SNU213, SNU410,
and SNU2913 cells treated with 0 or 1 µM AZD1775 for 48 hours. (E) Quantification of three independent Annexin V/PI 
assays. (F) Western blot analysis of apoptosis-related proteins in cells treated with 0, 0.1, or 1 µM AZD1775 for 48 hours. (G)
Cell cycle analysis of PI-stained PC cells treated with 0 or 1 µM AZD1775 for 24 hours. (H) Western blot analysis of cell cycle
arrest-related signaling molecules in cells treated with 0, 0.1, or 1 µM AZD1775 for 24 hours. *p < 0.05, **p < 0.01, ***p <
0.001. Experiments were repeated three times.
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(Fig. 1D and E) and concomitantly diminished the expression
of MCL-1 and elevated the expression of cleaved caspase-7
(Fig. 1F). Since WEE1 functions as a regulator of cell cycle
progression, we also assessed the proportion of cells in the
cell cycle phases by flow cytometric analysis of PI-stained
cells. As shown in Fig. 1G, a significantly greater proportion
of cells treated with AZD1775 than control was arrested in
S-phase. To verify this, we examined expression of phospho-
rylated replication protein A 32 (p-RPA32), an S-phase mar-
ker that binds to single-stranded DNA. Indeed, AZD1775
treatment for 24 hours resulted in increased p-RPA32 at ser-
ine 4 and 8, indicating that WEE1 inhibition leads to replica-
tion stress (Fig. 1H).

















































































Fig. 3.  Effect of WEE1 and ataxia telangiectasia mutated (ATM) co-inhibition on DNA damage. (A, B) Displayed Comet
Assay results after treated with 0, AZD1775 (1 µmol/L) alone, AZD0156 (1 µmol/L) alone, or both for 24 hours. Tail intensity
and moment were analyzed using the Comet Assay IV program. (C) The related DNA damage signals were detected after
exposed at combination treatment setting for 24 hours. **p < 0.01, ***p < 0.001. Experiments were repeated three times.
GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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3. Co-inhibition of WEE1 and ATM profoundly impairs 
activation of the HR pathway of DNA repair
Having evaluated the effects of AZD1775 as a single agent,
we asked whether WEE1 inhibition influences the activity of
other core members of the DDR, such as ATM or ATR. 
Indeed, we found that phosphorylation of ATM and ATR
was increased in cells treated for 24 hours with AZD1775
(Fig. 2A). Since AZD1775 had a greater effect on promoting
phosphorylation of ATM than of ATR, we next examined the
anti-proliferative effects of AZD1775 in combination with the
ATM inhibitor AZD0156 using the MTT assay. As shown in
Fig. 2B, the CI values of AZD0156 plus AZD1775 were less
than 1 for all four PC cell lines, indicating that the drugs had
a synergistic effect on proliferation.
To better understand the effects of combination AZD1775
and AZD0156 treatment, we examined the expression levels
of several molecules required for DNA repair via HR, after
treatment of cells for 72 hours with AZD0156 and/or AZD-
1775. We found that expression of p–NF-!B, Rad51, excision
repair cross-complementing protein 1, C-terminal binding
protein-interacting protein, and p-STAT1 were all downreg-
ulated by AZD1775 or AZD0156 when added alone, but a
greater effect was observed in cells co-treated with both
agents (Fig. 2C). These data suggest that co-inhibition of
WEE1 and ATM strongly blocks the HR pathway of DNA 
repair.
4. Co-inhibition of WEE1 and ATM synergistically induces
DNA damage
Having demonstrated that co-inhibition of WEE1 and
ATM blocks DNA repair, we next asked whether these
agents could induce DNA damage. We exposed the cells to
AZD1775 and/or AZD0156 for 24 hours, and then monitored
DNA fragmentation at the single-cell level using a comet
assay. We found that AZD1775 or AZD0156 alone promoted
DNA damage compared with control, but both agents in
combination caused markedly increased fragmentation, as
indicated by comet tail intensity and moment (Fig. 3A and
B). Consistent with this, western blot analysis revealed 
upregulated expression of the DNA damage marker "-H2AX,
with a greater effect observed in cells subjected to combina-
tion AZD1775 and AZD0156 treatment compared with
monotherapy (Fig. 3C).
5. Co-inhibition of WEE1 and ATM efficiently suppresses
PC cell migration 
To determine the consequences of WEE1 and ATM inhibi-
tion on PC cell function, we examined cell migration and 
invasion, which play well-characterized roles in cancer pro-
gression. Importantly, very few studies have evaluated the
effects of DDR-targeted agents on tumor cell migration. In
this study, Transwell migration assay was employed. Inter-
estingly, we found that cell migration and invasion of all four
PC cell lines were significantly suppressed by treatment with
1 µM AZD1775 or AZD0156 alone. However, the combina-
tion of both drugs resulted in efficiently inhibition of cell 
migration (Fig. 4A and B). Thus, WEE1 and ATM appear to
have previously unrecognized functions in promoting PC
cell migration.
The matrix metallopeptidases 9 and 2 (MMP-9 and MMP-
2) are known to be crucial for cancer metastasis and invasion
[17,18]. Therefore, we asked whether the effects of WEE1
and/or ATM inhibition on PC cell migration were mediated
via these enzymes. Western blot analysis revealed that treat-
ment with AZD1775 or AZD0156 for 24 hours slightly 
decreased the expression of the smaller, active form of MMP-
9 compared with control cells, and this effect was augmented
by co-treatment with both agents (Fig. 4C). In contrast, a 
reduction in active MMP-2 expression was only observed in
combination-treated Capan-1 and SNU410 cells (Fig. 4C). 
Next, we investigated the effects of DDR targeting on
chemokine expression in Capan-1 cells using a human cyto-
kine/chemokine array. We found that the chemokines inter-
leukin 8 (IL-8), CXCL1, CCL5, and CCL2 were significantly
downregulated by AZD1775 treatment, combination therapy
again showed an enhanced inhibitory effect on all four che-
mokines (Fig. 4D and E). Interestingly, previous work showed
that signaling via the receptors for these chemokines (CXC-
R2, CCR5, and CCR2), facilitate the release of MMP-9, which
contributes to enhanced angiogenesis and tumor metastasis
[19-21]. Collectively, our results suggest that AZD1775 and
AZD0156 act synergistically to suppress PC cell migration
by reducing chemokine expression and MMP-9 release. 
6. Co-inhibition of WEE1 and ATM downregulates PD-L1
expression in PC cells
Next, given that the pivotal status of PD-L1 expression in
cancer cell or cancer microenvironment [22], we explored the
potential interaction between the DDR and the anti-tumor
immune response by examining the effects of DDR-targeted
agents on total and cell surface expression of PD-L1 in PC
cells. Western blot analysis revealed that total cellular PD-L1
expression was decreased by AZD1775 or AZD0156 treat-
ment alone, but combination treatment was even more effec-
tive (Fig. 5A). This pattern was also observed when cell
surface PD-L1 expression was examined by flow cytometry,
particularly in SNU2913 cells, which express high PD-L1 lev-
els (Fig. 5B). 
To understand in more detail, the effects of WEE1 and ATM
inhibition on PD-L1 expression, we investigated potential
Cancer Res Treat. 2020;52(1):149-166
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Fig. 4.  Effect of WEE1 and ataxia telangiectasia mutated co-inhibition on migration of pancreatic cancer cells. (A) The anti-
migration effect was evaluated using cells with 0, AZD1775 1 µmol/L, or AZD0156 1 µmol/L or both. The image was cap-
tured at 24 hours after treatment. (B) The percentage of migratory cells was analyzed after image was captured. The data
represents three independent times. (Continued to the next page)
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mechanisms that regulate PD-L1: CMTM6, which is thought
to prevent PD-L1 degradation by lysosomes [12], and GSK-
3!, which has recently been identified as a novel regulator of
PD-L1 expression [23]. Western blot analysis of CMTM6 
expression showed a marked decrease in the protein levels
after treatment for 72 hours with AZD1775 and AZD0156, 
either alone or in combination (Fig. 5A). To probe CMTM6-
mediated regulation of PD-L1 further, we asked whether this
molecule is associated intracellularly by immunoprecipitat-
ing with anti–PD-L1 and probing for the presence of CMTM6
in the immunoprecipitates. We found that CMTM6 was pres-
ent in western blots of anti–PD-L1 immunoprecipitates, but
not control IgG immunoprecipitates, of all four PC cell lines
(Fig. 5C). Notably, immunoprecipitation (IP) with anti–
PD-L1 antibody showed the CMTM6–PD-L1 binding was 
decreased upon WEE1 or ATM inhibition, with the greatest
effects observed upon dual inhibition. However, IP of CMT-




















































































Fig. 4.  (Continued from the previous page) (C) Western blot analysis of migration-related molecules in cells treated as described
in panel A for 24 hours. MMP, matrix metallopeptidases; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. (D, E)
Human cytokine array analysis of Capan-1 cells treated as described for panel A for 24 hours. Spot intensities were quantified
using ImageJ software. 1, interleukin 8 (IL-8); 2, CXCL1; 3, CCL5; 4, CCL2. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Fig. 6.  (Continued from the previous page) (E, F) Mouse cytokine array analysis of serum collected from xenografted mice. Spot
intensities were measured using ImageJ software. 1, C5/C5a; 2, TIMP metallopeptidase inhibitor (TIMP-1); 3, macrophage
colony-stimulating factor (M-CSF); 4, CD54; 5, interleukin 16 (IL-16); 6, CXCL12. *p < 0.05, **p < 0.01, ***p < 0.001. 
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comparable decrease in CMTM6–PD-L1 binding, even in
cells co-treated with both AZD0156 and AZD1775 (Fig. 5C).
It is possible that the reduction of CMTM6 by AZD1775 and
AZD0156 led to decrease of CMTM6-PD-L1 bound form,
which ultimately increase the PD-L1 degradation by lyso-
some supported by previous report [12].
To determine whether PD-L1 expression might be affected
by the regulator GSK-3! in PC cells [23], we examined changes
in phosphorylated kinase expression in AZD1775 and/or
AZD0156-treated cells using a human phospho-kinase array.
We observed that while AZD1775 and AZD0156 both down-
regulated p–GSK-3! expression, the combination treatment
was more effective than either agent alone (Fig. 5D and E).
This indicated that PD-L1 expression not only controlled by
CMTM6 but also influenced by GSK-3! activity to a certain
extent. Moreover, we found the same inhibitory effects on
several other phospho-kinases, including phosphorylated
cAMP response element-binding protein (p-CREB), p-Src,
phosphorylated focal adhesion kinase (p-FAK), p-Yes, and
p-p53 (Fig. 5D and E). Taken together, these results indicate
that dual blockade of WEE1 and ATM may reduce PD-L1 
expression by downregulating the expression of CMTM6,
and inactive GSK-3!. 
7. Co-inhibition of WEE1 and ATM augmented anti-tumor
growth in Capan-1-xenograft model
To confirm the anti-tumor effect of AZD1775 and AZD-
0156 in vivo, Capan-1 xenograft model was established. 
Despite high PD-L1 expression was detected in vitro in SNU-
2913 cells, since Capan-1 was more tumorigenic than SNU-
2913, we selected Capan-1 xenograft models to conduct the
following experiments. Consistent with the in vitro observa-
tions, we found that single-agent treatment with AZD1775
or AZD0156 significantly decreased tumor growth, but the
combination treatment was markedly more effective than 
either agent alone (p < 0.05) (Fig. 6A). We observed no overt
evidence of drug toxicity, as reflected by a lack of significant
change in body weight (Fig. 6B). 
Next, we excised the tumors and performed immunohis-
tochemical (IHC) staining of various markers. As we had 
observed in vitro, PD-L1 expression was decreased by AZD-
1775 or AZD0156 monotherapy and decreased by combina-
tion treatment (Fig. 6C). Moreover, CD163, an M2-type
macrophage marker, was expressed at high levels in tumors
from control mice but at lower levels in tumors from
AZD1775- and/or AZD0156-treated mice (Fig. 6C). Combi-
nation treatment with both drugs also potently inhibited
staining of the proliferation marker Ki-67 and increased ter-
minal deoxynucleotidyl transferase dUTP nick end labeling
staining, which detects fragmented DNA (Fig. 6C). In paral-
lel, we performed western blot analysis to confirm our in
vitro findings in the isolated tumors. In line with the in vitro
results, we confirmed that AZD1775 treatment upregulated
p-ATM while combination treatment with AZD-1775 and the
ATM inhibitor reversed this. Moreover, the expression of 
p–NF-"B and CXCR2 were profoundly blocked by AZD1775
and/or AZD0156 treatment, and AZD1775 plus AZD0156
enhanced #-H2AX accumulation. Furthermore, we validated
the in vitro findings with PD-L1 and CMTM6 by confirming
that both proteins were downregulated by single- or dual-
agent treatment (Fig. 6D). 
Finally, we assessed the effects of the DDR-targeting
agents on immune cell activity by analyzing cytokine levels
in the sera of tumor-bearing mice. Using a mouse cytokine
array, we found that release of C5a, TIMP metallopeptidase
inhibitor 1 (TIMP-1), macrophage colony-stimulating factor,
CD54, IL-16, and CXCL12 were markedly reduced by AZD-
1775 and/or AZD0156 treatment, with larger effects obser-
ved in drug combination-treated mice (Fig. 6E and F). Collec-
tively, these in vivo data confirm that dual targeting of the
DDR pathway components WEE1 and ATM profoundly sup-
press tumor growth in vivo compared with blockade of either
molecule alone.
Discussion
Although ATM is a tumor suppressor gene, both of WEE1
and ATM promote DNA repair to maintain cell survival dur-
ing the progression of the cancers [24]. Inhibition of WEE1
and ATM activity are our opportunity to kill the cancers by
facilitating DNA damage.
In this study, we demonstrate for the first time that target-
ing the DDR by inhibition of WEE1 has anti-tumor effects in
PC and that co-inhibition of WEE1 and ATM amplifies these
effects. We also identified crosstalk between the DDR path-
way and immune system by demonstrating DDR-dependent
regulation of PD-L1 expression in PC cells. 
One of the main findings of this study is that dual inhibi-
tion of WEE1 and ATM has profound effects on PC cell 
migration. Only a few studies have been performed on the
anti-migratory effects of DDR-acting agents. One report
showed that AZD1775 inhibits the migration of gastric cancer
cells, although the mechanism of action was not elucidated
[25]. Another study suggested that ATM might promote cell
migration by regulating IL-8 expression independently of its
role in DNA double-strand break repair [26]. We found that
WEE1 and ATM co-inhibition reduced the expression of
MMP-9, IL-8, CXCL1, CCL2, and CCL5, which is consistent
with an anti-migratory effect. This is the first demonstration
of the involvement of WEE1 or ATM in MMP-9 or IL-8 reg-
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ulation. Moreover, downregulation of CXCR2, which is the
IL-8 and CXCL1 receptor, in PC tumors was confirmed in our
in vivo experiments. Although CXCR2 inhibition was shown
to profoundly suppress metastasis and augments anti–PD-1
therapy in PC [10], the current study is the first to examine
CXCR2 expression in PC. Since CXCR2 and CCR2 are also
expressed by M2 macrophages, we speculate that combina-
tion AZD1775 and AZD0156 treatment might impair M2
type polarization [27]. In addition, the involvement of Src
and FAK in promoting cell migration and invasion is well
known [28], and a recent report implicates a similar role for
p-CREB [29]. Thus, our finding that expression of p-CREB,
p-Src, p-Yes, and p-FAK are profoundly inhibited by WEE1
and ATM co-inhibition is consistent with a role for these mol-
ecules in PC cell migration. Prior to this study, there had
been no reports of a relationship between Src/FAK/CREB
and the DDR pathway in PC.
An interesting recent study reported that PARP inhibition
upregulates PD-L1 expression in breast cancer via inactiva-
tion of GSK-3! [16]. We also found a similar increase in 
PD-L1 expression in PARP inhibitor (Olaparib)-treated PC
cells (data not shown). In contrast, the present study showed
here that targeting of the DDR by WEE1 and/or ATM inhi-
bition reduced PD-L1 expression concomitantly with down-
regulation of p–GSK-3! Ser9 level, the inactive form of GSK-
3!. This mechanism might at least partly explain the reduc-
tion in PD-L1 induced by WEE1 and/or ATM inhibition. It
is interesting to note that PARP, WEE1, and ATM have dis-
tinct effects on PD-L1 expression, despite the fact that they
are all core members of the DDR signaling network. Thus,
while PARP inhibition increases PD-L1 expression by enhan-
cing GSK-3! inactivation, WEE1 and/or ATM inhibition
does the opposite by decreasing the expression of inactive
GSK-3!. 
Among the mechanisms known to regulate PD-L1 expres-
sion, many act at the transcriptional level, including the JAK-
STAT pathway, c-Myc, and NF-"B [15,30,31]. Consistent with
this literature, we also observed a reduction in p-STAT-1 and
p-NF-"B concomitant with PD-L1 downregulation in WEE1
and/or ATM inhibitor-treated cells. More recently, Burr and
colleagues used CRISPR/Cas9 technology to screen approx-
imately 20,000 genes in the human PC cell line BxPC-3, and
they identified a novel protein, CMTM6, as a major regulator
of PD-L1 expression [12]. Importantly, we observed that
CMTM6 binds to PD-L1 in PC cells and that CMTM6 expres-
sion was reduced upon inhibition of WEE1 and/or ATM. As
mentioned earlier, CMTM6 could rescue and recycle the 
PD-L1 from the lysosome to the cell surface. More recently,
an interesting study revealed that HIP1R facilitates the deli-
very of PD-L1 to the lysosome [32]. Here, we speculated two
potential mechanisms of the CMTM6 reduction by WEE1 or
ATM. First of all, WEE1 or ATM might post-transcriptionally
increase the HIP1R expression and compete for CMTM6 to
bind with PD-L1. Secondly, CMTM6 might be transcription-
ally downregulated by WEE1 or ATM, and these events fur-
ther disrupt the interaction between PD-L1 and CMTM6. The
mechanism by which DDR targeting blocks CMTM6 expres-
sion remains to be clarified.
As mentioned earlier, KRAS and TP53 are frequently 
mutated in PC. Recent work suggests that KRAS mutant can-
cer cells can enhance the recruitment of MDSCs and M2
macrophages to the tumor, thereby contributing to evasion
of the immune response. M2 macrophages can also be recrui-
ted by cancer cells carrying mutant TP53 [9]. These macro-
phages promote tumor evasion through multiple mecha-
nisms, including enhanced angiogenesis and tissue remod-
eling, recruitment of MDSCs and CAFs, and inhibition of T
cell function and proliferation, thus enhancing metastasis
and invasion [33]. Here, we evaluated M2 macrophage 
recruitment to the tumor in the mouse xenograft model by
IHC staining of CD163, and we found that the high basal lev-
els of tumor-associated CD163+ cells were markedly decrea-
sed by AZD1775 and/or AZD0156 treatment. This finding
supports the possibility that combination therapy suppresses
recruitment of M2 macrophages to the tumor, and it will be
of interest to understand how other cells in the tumor micro-
environment are affected by DDR-targeting agents. 
We used high concentrations of WEE1 inhibitor (AZD1775-
1 µM) and ATM inhibitor (AZD0156 1 µM) in current in vitro
experiments considering the active pharmacology of com-
pounds. Particularly, AZD0156 1 µM might have off-target
effects. 
Taken together, our results demonstrate that DDR-target-
ing agents such as WEE1 and ATM inhibitors have potent,
synergistic anti-tumor effects in PC. We also identified cro-
sstalk between the DDR and immune response in PC, since
WEE1/ATM inhibition downregulates CXCR2, CD163, and
PD-L1 expression, the latter by blocking expression of inac-
tive p–GSK-3! and CMTM6. The findings in this study sup-
port further clinical development of DDR-targeting strategies
for the treatment of PC.
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